Previous 10 | Next 10 |
2023-05-13 08:00:00 ET The stock market's short-term volatility can sometimes cloud investors' judgment and cause panic selling. But history has demonstrated time and again that a buy-and-hold strategy is one of the best ways for the average person to generate wealth. So it pays to target s...
2023-05-11 16:18:07 ET Summary BioXcel Therapeutics, Inc. is currently in exciting times, awaiting very important clinical trial results in the coming weeks. The recently released BioXcel Therapeutics first-quarter results provided a low revenue figure for IGALMI, however, the mar...
2023-05-09 15:37:01 ET Axsome Therapeutics (NASDAQ: AXSM) stood out last year. The biotech began selling its first two products: Sunosi, a sleep disorder drug it acquired from Jazz Pharmaceuticals ; and Auvelity, an antidepressant it developed in house. Thanks to those successes...
2023-05-09 14:17:57 ET Summary Axsome reported its Q1'23 earnings yesterday - net loss was $(0.26) per share. The company's 2 commercial products - newly approved Auvelity and Sunosi, acquired from Jazz Pharmaceuticals earned $29m. Axsome smashed analysts' estimates thanks to ...
2023-05-08 14:22:05 ET Axsome Therapeutics, Inc. (AXSM) Q1 2023 Earnings Conference Call May 8, 2023 08:00 ET Company Participants Mark Jacobson - Investor Relations Herriot Tabuteau - Chief Executive Officer Nick Pizzie - Chief Financial Officer Lori Englebe...
2023-05-08 14:00:35 ET Image source: The Motley Fool. Axsome Therapeutics (NASDAQ: AXSM) Q1 2023 Earnings Call May 08, 2023 , 8:00 a.m. ET Operator Continue reading For further details see: Axsome Therapeutics (AXSM) Q1 2023 Earnings Call...
2023-05-08 09:28:58 ET Axsome Therapeutics ( NASDAQ: AXSM ) added ~6% pre-market after its Q1 2023 results as investors turned attention to sales of its newly approved depression therapy, Auvelity, during its first full quarter of commercial launch. In October, Axsome ( AX...
2023-05-08 07:03:54 ET Axsome Therapeutics press release ( NASDAQ: AXSM ): Q1 EPS of -$0.26 may not be comparable to consensus of -$1.29. Revenue of $94.6M beats by $69.12M . Auvelity 1Q 2023 net product sales of $15.7 million Total 1Q 2023 net prod...
Auvelity ® 1Q 2023 net product sales of $15.7 million Total 1Q 2023 net product sales of $28.6 million Total 1Q 2023 revenue of $94.6 million, including Sunosi ® ex-U.S. license agreement upfront payment Company to host conference call tod...
2023-05-05 12:17:49 ET Axsome Therapeutics ( NASDAQ: AXSM ) is scheduled to announce Q1 earnings results on Monday, May 8th, before market open. The consensus EPS Estimate is -$1.13 (-9.7% Y/Y) and the consensus Revenue Estimate is $25.48M Over the last 1 year, AXSM ...
News, Short Squeeze, Breakout and More Instantly...
Axsome Therapeutics Inc. Company Name:
AXSM Stock Symbol:
NASDAQ Market:
Axsome Therapeutics Inc. Website:
PALM BEACH, Fla., July 25, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The fibromyalgia treatment market has witnessed positive growth trends over the past few years. There is higher disease awareness due to growth in diagnosis rates and growing awareness and concern for this se...
2024-07-15 07:15:00 ET Any stock can have an impressive run, especially when broader equities are experiencing a bull market. Significantly fewer stocks can perform well through good and not-so-good times and deliver excellent returns over long periods. These are precisely the sort of corpo...
NEW YORK, July 11, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced it will report its financial results for the second quarter of ...